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ABSTRACT
Diesel exhaust particles (DEP) represent a key component of particulate matter
poIlution and a serious cardiopulmonary health risk, as these particles have been
associated with increased morbidity and mortality foIlowing exposure. In this study, we
investigated the immunomodulatory properties of DEP on helper T celIs by measuring
changes in activation, cytokine production, and viability. The expression of CD40L, a
key regulatory protein, was increased by DEP in the absence of physiologic stimuli
without paraIlel increases in the expression of CD25 and CD69 activation markers.
Additional studies utilizing a variety of T ceIl stimuli, including T ceIl receptor signaling
and CD28 co stimulation, showed consistent and reproducible increases in the expression
of CD40L with negligible effects on other activation markers. Further studies
demonstrated that the ability of DEP to augment CD40L production was restricted to the
induction of the membrane-bound form of this protein, as soluble CD40L (sCD40L) was
generally decreased. However, an increase in both membrane and sCD40L was observed
in the context of cAMP signaling, which may have implications for at-tisk populations
utilizing the therapeutic effects of this important second messenger, including beta (p)adrenergic agonists bronchodilators for the treatment of respiratory disease. Additional
studies were performed to evaluate changes in the production of IL-8 and IL-17
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cytokines. DEP produced no appreciable effect on IL-8 generation, but inhibited the
production of IL- 17. Evaluation of cytotoxicity indicated D EP had no measurable effect
on T cell viability in resting cells. Collectively, these findings demonstrate an
immunomodulatory capacity ofDEP and may, in part, provide a mechanism explaining
the contributions of DEP to the observed changes in morbidity and mortality. Given the
importance of CD40L signaling in normal immune function, the findings that CD40L
expression was increased regardless of the cellular activation status may be very relevant
to diseases where the immune system contributes to pathogenic processes.
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INTRODUCTION
As stated by the World Health Organization, unlimited and free access to clean air
of acceptable quality is a fundamental human necessity and right (World Health
Organization, 2004). In an attempt to achieve this for all Americans, the United States
Department of Environmental Quality issued the first National Ambient Air Quality
Standards in 1971 to address the major environmental and health challenges of particulate
matter (PM) pollution facing our society. Since then, as scientific and epidemiologic data
has accumulated, the initial standards set forth have been improved to address the serious
effects of respirable particulates on human health with the latest version in final review as
of December 2008 (United States Environmental Protection Agency, 2008). PM is a
heterogeneous substance, composed of extremely small particles and liquid droplets,
known to negatively affect overall health as measured by the observed increases in PMrelated morbidity and mortality. The largest contributing source of PM pollution, diesel
exhaust particles (DEP), represents a complex, anthropogenic pollutant produced during
the process of diesel fuel combustion that has been directly linked to adverse
cardiovascular, neurologic, and respiratory effects (Krivoshto, Richards, Albertson, &
Derlet, 2008; Pope, III & Dockery, 2006; Ris, 2007). Extensive evidence exists that
assigns a causal role for PM and DEP in the development and exacerbation of asthma and
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other allergic diseases (Koren, 1995; Holguin, 2008; Pandya, Solomon, Kinner, &
Balmes, 2002). Due to the fact that asthma involves an inflammatory immune response,
many studies have implicated DEP as an adjuvant for allergic diseases by altering normal
immune system activity potentially contributing to the increased prevalence and severity
of this disease. Of the multitude of cells comprising the human immune system, helper T
cells are central for proper immune function as this cell type communicates with other
cells to mount a rapid and efficient immune response. However, improper function of
helper T cells has been assigned a causal role in the development of certain allergic and
autoimmune diseases. Therefore, it is important to understand how DEP exposure may
affect the function of this cell and thereby contribute to the pathogenesis of diseases that
are complicated by exposure to air pollution. The consequence of this line of research
will hopefully achieve important short and long term goals: to properly diagnose and treat
life threatening events, reduce PM-associated morbidity, and reinforce the need for
higher emission standards, resulting in an improved quality of life for individuals living
in industrialized societies.

Air Pollution

The linkage between air pollution and negative health effects is not a novel
concept. Reports documenting the negative effects of air pollution exist from as early as
the 1930's in Belgium, where a dense fog of industrial pollutants covered the Meuse
Valley and resulted in 60 deaths attributed to severe respiratory distress (Nemery, Hoet,
& Nemmar, 2001). When the fog lifted, rapid improvement of respiratory symptoms was

achieved. Similar events occurred in the next decades in Donora, PA and in London.
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The London fog of 1952 has received notoriety as over 4000 individuals succumbed to
combined cardiovascular and respiratory complications as a result of air pollution
exposure (Logan, 1953). A subsequent fog event in London in 1956 reported 1000
deaths with a 94% increase in bronchitis-related deaths (Logan, 1956). Therefore,
extensive research has been conducted to define air pollution, understand the mechanisms
by which it alters human health, and implement stringent air quality standards.
Air pollution comes from a variety of sources, which results in a complex mixture
of particle and gas phase pollutants. Most epidemiologic studies on air pollution have
focused on understanding the health effects of six principal or criteria air pollutants, as
defined by the Clean Air Act established in 1963, routinely monitored by the
Environmental Protection Agency (EPA) and World Health Organization (Holguin,
2008). Guidelines for exposure to these pollutants; ozone, nitrogen dioxide, sulfur
dioxide, lead, carbon monoxide, and particulate matter, has been established by the
National Ambient Air Quality Standards. Each criteria pollutant is derived from different
emission sources, which yield pollutants that exhibit variations in chemical composition.
This results in different toxicity profiles and unfavorable health effects dependent on the
circumstances surrounding the combustion process such as season, fuel source, and
geographic location (McCreanor et aI., 2007). Of these identified pollutants, the EPA
identifies both ozone and particulate matter pollution to be the most concerning health
threats (United States Environmental Protection Agency, 2009).
Particulate matter (PM) is currently classified based on size of the inhalable
particles, with a direct relationship between particle size and detrimental health effects
(Siegel et aI., 2004). Coarse PM (PM IO) includes particles that range from 2.5 - 10
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micrometers (/lm) in diameter with fine PM (PM2s ) being 2.5 /lm in diameter and
smaller. Another recognized category is ultrafine particles (PM,o), with diameters less
than 1.0 /lm, which rapidly aggregate to become components of PM25 (Pope, III &
Dockery, 2006). Coarse and fine particulates differ not only in their size and physical
properties, but also in their chemical composition. PM JO is largely composed of
geological materials, in contrast to PM2.5 and PM,o, which have larger fractions of
elemental and organic carbon (Hetland et aI., 2005). Coarse particulate matter is
primarily derived from a suspension of dispersed ground dust in addition to soil, pollen,
spores, and other materials (Pope, III & Dockery, 2006; Holgate et aI., 2003). Fine and
ultrafine particulate matter is produced as a result of different combustion processes such
as wood burning, smelting, and cement processing. However, the major contributor to
fine and ultrafine particulate matter is vehicle fuel exhaust (Wichmann, 2007). In
general, all classes of PM pollution represent a major environmental health concern and
epidemiological studies have identified a positive correlation between levels of PM and
PM-related morbidity and mortality highlighted by increasing hospital emergency room
visits and admissions (Hesterberg et aI., 2009; Bunn, III et aI., 2004; Laden, Schwartz,
Speizer & Dockery, 2006). While all categories of inhalable PM are linked with negative
health effects; the smaller, inhalable particles playa larger role in cardiovascular,
neurologic, and respiratory disease as these particles easily pass through the nasal
passage, into the lungs, and out into circulation allowing for penetration of these particles
throughout the entire body. One specific pollutant that has garnered extensive attention
for its association with negative health effects are DEP.
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Diesel Exhaust
Diesel exhaust is a highly complex mixture formed during the combustion process
resulting in the production of hundreds of different components, either in the gas or solid
form with solid particulates in the fine and ultra-fine size PM categories (Krivoshto,
Richards, Albertson, & Derlet, 2008; Wichmann, 2007). This vehicle emission source
represents the largest single source of airborne PM with diesel engines emitting higher
levels of gaseous emissions and up to 100 times more particles compared with modem
gasoline engines (Riedl & Diaz-Sanchez, 2005). Despite the unfavorable impacts to our
environment and human health, diesel is the primary source of fuel for mass
transportation in the United States based on increased efficiency and endurance of diesel
engines in comparison to gasoline engines (Krivoshto, Richards, Albertson, & Derlet,
2008). Other industrialized countries are even further dependent upon diesel fuel. In
1998, it was reported that 18% of Japanese motor vehicles relied upon diesel fuel with
98% of the nation's buses running on diesel fuel. While 18% may not be viewed as a
substantial value, the emissions resulting from these vehicles accounted for almost 100%
of emission-related PM pollution (Kagawa, 2002).
Recognized as a heterogeneous compound; the components of diesel exhaust may
include elemental carbon, polycyclic aromatic hydrocarbons, carbon monoxide, nitrogen
and sulfur compounds. To date, over 450 different compounds have been identified in
diesel exhaust with 40 recognized hazardous pollutants (lnadera, 2006; Annesi-Maesano
et aI., 2007). Based on the size ofDEP, with 80-95% of the particles in diesel exhaust
measuring less than 2.5 ).tm in diameter, these particles bypass the protective barriers of
our lungs and penetrate deep into the respiratory system (Ris, 2007). The complexity of
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diesel exhaust is further enhanced by its elemental carbon core, which has the ability to
adsorb hundreds of chemicals and transition metals (Riedl & Diaz-Sanchez, 2005). The
large surface area of the smaller particles allows for greater chemical adsorption of
compounds from the surrounding environment, which translates into increased biological
effect (United States Environmental Protection Agency, 2002). This idea is further
supported by studies which have identified the adverse effects of DEP is not necessarily
due to the carbon core but the chemical constituents found in DEP samples (Siegel et aI.,
2004). The inhalation of particles with adsorbed compounds transports novel or foreign
materials deep into our circulation, which may be recognized by the organ system
responsible for eliminating foreign invaders, the immune system.
As previously mentioned, the severe fog incidents occurring in Europe were
linked to a substantial increase in cardiovascular and respiratory mortality (Pope, III &
Dockery, 2006). In the context ofDEP, the ability of the nanoparticle component to
migrate through the lung and into the circulatory system has been directly linked to
cardiovascular mortality as viewed by alterations in atherosclerosis and acute myocardial
infarction and physical changes that occur in the heart and blood vessels following DEP
exposure (Mills et aI., 2007; Wichmann, 2007). As understanding of cardiovascular
events grows, altered immune cell activity is now recognized as a contributor to disease
progression. Respiratory mortality is also thought to involve the immune system as
diseases such as chronic obstructive pulmonary disease and asthma are exacerbated by
DEP exposure and clearly involve an inflammatory component (Inadera, 2006).
However, the exact mechanisms by which DEP alter immune system function has yet to
be fully elucidated and are a goal of the present study.
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The Immune System

The human immune system is a highly complex organ system which has evolved
to prevent illness from a variety of pathogens and foreign invaders. This protection is
achieved through the action of two distinct, yet intertwined branches: innate and adaptive
immunity (Huston, 1997). Innate immunity provides rapid, yet non-specific, protection
from foreign invaders, as the cell types of this branch are present prior to exposure to
infectious agents. In contrast, the adaptive branch provides an antigen (A g) specific
response, where Ags are defined as molecules representing small fragments of a pathogen
or foreign material, recognized by the immune system with immunological memory
resulting following Ag encounter (Delves & Roitt, 2000). The ability to recognize self
from non-self is a key feature of the adaptive immune system, which can be further
divided into the cell-mediated and humoral systems, with white blood cells central to
proper functioning. Humoral immunity involves the action of B cells to encounter,
process, and produce Ag-specific antibodies following Ag encounter. The cell-mediated
arm of the immune system provides a highly coordinated defense system through the
action of T cells, which recognize the processed Ag and in turn direct the immune
response by providing proper signals to multiple other immune cells (Delves & Roitt,
2000). Therefore, the crucial interactions occurring between Band T cells must be
tightly regulated to provide adequate protection, and this high level of control is achieved
through the activity of a specific T cell, the T helper lymphocyte.
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Helper T (T H) Cells
T lymphocytes exist as two subpopulations, helper T (TH) cells and cytotoxic T
(Tc) cells, and are identified based on the expression of distinct cell surface receptors. TH
cells express a receptor known as CD4 (Qluster of Determination #1) and T c cells express
the CD8 receptor. While Tc cells are known for their ability to eliminate virally infected
cells or cancer cell, T H cells are recognized as crucial immune system directors (Behrens
et aI., 2004). T H cells exert this level of regulation via involvement in multiple signaling
pathways which control the action of other immune cells following Ag encounter. Helper
T cells are able to recognize Ag through interactions with Ag in the context of the major
histocompatibility complex II (MHC II), a protein expressed by antigen presenting cells
(APC) such as B cells, dendritic cells, and macrophages (Davis & Bjorkman, 1988). The
importance of T H cells is highlighted by the human immunodeficiency virus, which may
develop into human acquired immunodeficiency syndrome (AIDS) as the virus invades
and eliminates T H cells, resulting in an immunocomprimised state with reduced ability to
prevent infection as a result of foreign pathogens. The fatality of AIDS is directly related
to secondary infections, where the immune system cannot respond properly due to the
decreased number of circulating T H cells (Varbanov, Espert, & Biard-Piechaczyk, 2006).
Based on the integral role of THin proper immune function, the activity of this cell type
must be tightly regulated as improper T H cell activation is a key hallmark of a multitude
of disorders including asthma, multiple sclerosis, and cardiopulmonary disease.
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T Cell Receptor and T Cell Activation
Central to the function of TH cells is the presence of a T cell receptor (TCR), a
multi subunit protein required to recognize Ag presented via MHCII (Rojo, Bello, &
Portoles,2008). The TCR is composed of two transmembrane polypeptides,
with one variable and one constant domain (Delves & Roitt, 2000). The

a/~

or y18,

a/~

configuration is the most prominent TCR combination and is responsible for foreign Ag
recognition. The ability to recognize Ag is accomplished by the TCR in conjunction with
the CD3 signaling complex, composed of five transmembrane polypeptides
11) that assemble to form three dimers (y£, 8£, and

~~

(y,£,8,~,

and

or 1111). CD3 derived signal

transduction, which results in T cell activation, proliferation, and differentiation cannot
occur unless the TCR-CD3 complex is accurately assembled (Feito et aI., 2002; Davis &
Bjorkman, 1988).
While the presence of the TCR-CD3 complex is essential for T cell function,
additional cell surface proteins are stimulated during Ag encounter to provide
costimulatory signals, which augment the TCR derived signal. The most prominent
protein in this category, CD28, is displayed constitutively from all T H cells and interacts
with B cells via the B7 family of proteins (Lenschow, Walunas, & Bluestone, 1996).
Following TCR encounter with Ag, the CD281B7 signaling pathway is activated, further
inducing T cell activation via increased signal transduction and lowered T cell activation
threshold.
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T H Cell Signal Transduction

Activation of TH cells is tightly regulated via interactions between the TCR and
Ag-MHCII in addition to the role of costimulatory pathways. Upon TCR-Ag encounter,
T cell activation is achieved via increased gene transcription. This transcription results in
the production of numerous proteins responsible for foreign Ag recognition and removal.

In order to achieve this activation state, signal transduction must occur within the TH cell
involving two distinct signaling pathways: calcium and protein kinase C (PKC).

Calcium (Ca2+) Signaling
Intracellular calcium signaling is achieved following TCRlCD3 stimulation,
which results in the mobilization of internal calcium stores (Rao, Luo, & Hogan, 1997).
This stepwise process begins with the phosphorylation of phospholipase C, which cleaves
phosphoinositol biphosphate (PIP 2) into two important second messengers: inositol 1,4,5triphosphate (IP 3) and diacylglyceral (DAG). Ofthese two second messengers, IP 3 binds
to Ca2+ receptors in the surface of the cell's endoplasmic reticulum, which opens Ca2+
channels resulting in an increase in cytoplasmic Ca2+. Additionally, calcium channels in
the plasma membrane are opened, allowing an influx of ci+ further increasing
intracellular Ca2+ (Kindt, Goldsby, & Osborne, 2007). Once Ca2+ has entered the
cytoplasm, it acts upon a group of calcium-sensitive proteins including calmodulin,
calcineurin, and the family of nuclear factor of activated T cells (NF AT) transcription
factors. The increased intracellular Ca2+ combined with the activity of calcium-sensitive
proteins causes a synergistic increase in gene transcription, which results in the
translation of key immunoregulatory proteins (Rao, Luo, & Hogan, 1997).
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Protein Kinase C (PKC) Signaling
Following the phosphorylation of phospholipase C, cleavage ofPIP 2 into second
messengers IP3 and DAG occurs with IP3 influencing Ca2+ signaling and DAG directly
activating protein kinase C (PKC)-dependent signaling processes (Kindt, Goldsby, &
Osborne, 2007). The PKC family is a large family of serine/threonine kinases with ten
identified isoforms that are widely distributed in mammalian tissues and are categorized
into three groups based on their mode of action (Tan & Parker, 2003). Upon activation,
PKC moves from the cytosol to the cell membrane, where it phosphorylates serine and
threonine amino acids on transcription factors important to T cell activation, such as the
hcB/NFKB complex. Upon phosphorylation, NFKB is released from IKB and translocates
to the nucleus, resulting in an increase in gene transcription and translation of additional
immunoregulatory proteins (Kindt, Goldsby, & Osborne, 2007). The combined action of
Ca2+ and PKC signaling provides the proper stimuli required for T cell activation.

T Cell Activation: Membrane Bound Markers
Following ligation of the T cell receptor, T cell activation is achieved and key
immunomodulatory proteins are produced, including both membrane-bound and secreted
soluble proteins that are crucial for mounting an immune response (Kindt, Goldsby, &
Osborne, 2007). Membrane-bound proteins are frequently classified as "activation
markers" as these proteins are not constitutively expressed and their level of expression is
frequently correlated with the degree of activation stimulus the T cell received. In
addition, membrane-bound proteins can have profound effects on the immune system as
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they can act as immune system activators themselves. Examples of such membranebound proteins are CD40 ligand (CD40L), CD69, and CD25.

CD40 Ligand
Helper T cells exert a high level of control over immune system function partially
through the tightly regulated expression of a key protein, CD40 ligand (CD40L)
(Schonbeck, Mach, & Libby, 2000). CD40L (CDI54, gp39, TRAP) is a type II
transmembrane protein, found on activated TH cells in addition to other immune and nonimmune cells such as platelets, basophils, eosinophils, natural killer (NK) cells, B cells,
mast cells, dendritic cells, smooth muscle, and epithelial cells, and belongs to the tumor
necrosis family (TN F) superfamily (Schonbeck & Libby, 2001). This family of proteins
is integral in the control of immune cellular functions such as regulation of proliferation,
differentiation, and apoptosis (programmed cell death). Specifically, CD40L expression
is essential for proper function of the adaptive immune system where this protein has the
ability to regulate the humoral and cell-mediated branches via the aforementioned control
of cellular functions (Banchereau et al., 1994). Additionally, the expression of CD40L is
considered to be a rate-limiting step in immune system function as small changes in
CD40L can have significant biological effects given that a 1.1 to 2.0 fold increase in
CD40L can result in a 4- to 5 fold increase in B cell antibody (Ab) production and a
similar increase in B cell proliferation and monocyte matrix metalloproteinase production
(Perez-Melgosa, Hollenbaugh, & Wilson, 1999; Mach et al., 1999; Hermann, Van
Kooten, Gaillard, Banchereau, & Blanchard, 1995). This key protein is involved in the
regulation of both humoral and cell-mediated immunity via interactions with its receptor,
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CD40 yielding enhanced B cell survival, growth, differentiation, Ab isotype switching,
and IgE production in addition to providing signals to increase T cell cytotoxicity,
macropharge tumoricidal activity, and enhanced expression of pro-inflammatory
cytokines (Schonbeck, Mach, & Libby, 2000; Banchereau et aI., 1994). CD40L is
essential to proper immune function, as inappropriate expression of this protein has been
linked to human diseases such as systemic lupus erythematosus (SLE), atherosclerosis,
autoimmune diabetes, and multiple sclerosis (MS) (Schonbeck & Libby, 2001; Xu &
Song, 2004). The importance ofCD40L is further highlighted by X-linked Hyper IgM
syndrome, an immunodeficiency where individuals experience repeated infections,
possess defects in cell-mediated immunity and germinal center formation, and the
inability of B cells to express IgG, IgA, and IgE Ab isoforms as a result of non-functional
CD40L expression (Schneider, 2000).

The expression of CD69 appears to be the earliest inducible cell surface
glycoprotein appearing after immune system activation begins (Cambiaggi et aI., 1992).
Also known as the activation-inducer molecule or very early activation marker, CD69 is
rapidly and transiently expressed by a host of immune cells such as B cells, NK cells,
neutrophils, and T cells (Kindt, Goldsby, & Osborne, 2007). The exact function of CD69
has yet to be determined as the ligand for CD69 has not been identified, however it is
theorized that CD69 may be an immunomodulatory protein with activation and
regulatory properties CD69 expression is also associated with high levels of
inflammation and RA, asthma, and acquired immunodeficiency syndrome disease states
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(Marzio, MaueI, & Betz-Corradin, 1999). Although the precise biological function of
CD69 has yet to be completely elucidated, it is very commonly used as a marker of
immune cell activation as described in this study (Marzio, MaueI, & Betz-Corradin,
1999; Sancho, Gomez, & Sanchez-Madrid, 2005).

Also known as the low-affinity IL-2 receptor or T-cell activation antigen, CD25 is
expressed by activated T cells, B cells, macrophages, and other immune cell types.
Additionally, CD4+ T cells bearing CD25 surface proteins have recently been identified
as a unique T cell subset known as the regulatory T cells, playing a large role in the
development of immune system tolerance, although these cells represent a distinct
cellular phenotype from stimulated TH cells displaying CD25 (Nelson, 2004). Similar to
CD40L and CD69, this protein is expressed at low levels in the absence of stimuli and is
rapidly and transiently expressed following TCR signaling. This membrane-bound
protein is a fundamental component of the IL-2/IL-2 receptor signaling cascade resulting
in increased T cell activation and proliferation. Additionally, this receptor signaling
complex is involved in the growth and differentiation of other immune cells such as B
cells, NK cells, and macrophages (Kindt, Goldsby, & Osborne, 2007).

T Cell Activation: Soluble Markers

In addition to the production of membrane-bound proteins, soluble
immunomodulatory factors may be produced and secreted by activated T cells. These
soluble factors may be truncated versions of the membrane-bound protein produced by
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cleavage events, i.e. soluble CD40L, or directly secreted proteins such as cytokines and
chemokines, i.e. interleukins (lL). These factors utilize the circulatory system to exert a
high level of control over immune system function at distant sites in the body, allowing
for removal of pathogens with minimal delay (Delves & Roitt, 2000). T Hcells are
classified in two established categories in regards to the soluble cytokines in which they
produce, type 1 (T HI) or type 2 (TH2) cytokines. Essential for cell-mediated functions,
THI cytokines are typically associated with inflammatory-based immune responses,
focusing the immune system towards removal of viral and intracellular pathogens. In
contrast, TH2 cytokines function to remove extracellular pathogens by stimulating
eosinophils and B cells, resulting in increased Ab production (Kindt, Goldsby, &
Osborne, 2007; Zhu & Paul, 2008). The tightly controlled regulation of these cytokines is
essential as they may be both pro-inflammatory and anti-inflammatory in nature and
altered cytokine production may be associated with different disease states, including
asthma where a T H2 cytokine environment is favored and contributes to disease
pathogenesis (Delves & Roitt, 2000; Holgate, 2008).

Soluble CD40 Ligand
As mentioned above, TH cells produce a key immunoregulatory membrane-bound
protein called CD40L. However, a soluble form of this protein, soluble CD40L
(sCD40L), also exists and represents a truncated version of the full length protein created
by proteolytic cleavage of the transmembrane domain of membrane CD40L (Hirohata,
1999). Despite its truncated state, sCD40L possesses significant biological activity and
can induce the CD40 signaling cascade at distant sites via circulatory system distribution,
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albeit to a lesser extent than membrane CD40L (Ludewig, Henn, Schroder, Graf, &
Kroczek, 1996). Additionally, our lab has shown that membrane CD40L and sCD40L
are differentially regulated in response to the various TCR and costimulatory signaling
pathways (Matthies, Newman, Hodzic, & Wingett, 2006). Similar to membrane CD40L,
sCD40L expression must be tightly regulated as elevated serum levels are associated with
diseases such as atherosclerosis, hypercholesterolemia, and SLE (Aukrust et al., 1999;
Kato et al., 1999; Vishnevetsky, Kiyanista, & Gandhi, 2004).
While the exact proteolytic cleavage mechanisms responsible for sCD40L
production are still being investigated, the process of ectodomain shedding is becoming
recognized for its role in producing soluble factors. The process of ectodomain shedding
is thought to involve a family of proteins, adamlysins, which include matrix
metalloproteinases (Black & White, 1998). Specifically, ADAM (a disintegrin and
metalloprotease domain) proteins have been implicated in ectodomain shedding and
research conducted by our lab implicates ADAM-l 0 as a key proteinase involved in the
production of sCD40L derived from T cells (Matthies, Newman, Hodzic, & Wingett,
2006; Schlondorff & Blobel, 1999).

Interleukin 8
Interleukin 8 (IL-8) is a prototypic member of the CXC family of chemokines
produced by many different cells types, including T cells, in response to proinflammatory signals (Kindt, Goldsby, & Osborne, 2007). Also known as the neutrophil
activating protein, IL-8 is a chemoattractant cytokine involved in the chemotaxis and
activation of neutrophils, in addition to basophils and some lymphocytes (Rajarathnam et

17
aI., 1994). IL-8 is produced in response to a wide variety of stimuli and is recognized as
a pro-inflammatory cytokine that is linked with chronic inflammatory diseases such as
inflammatory bowel disease and atherosclerosis, as increased IL-8 level expression is
positively correlated with progression of these diseases (Grimm, Elsbury, Pavli, & Doe,
1996; Apostolakis, Vogiatzi, Amanatidou, & Spandidos, 2009). In terms of asthma and
other chronic respiratory disorders, the activation and recruitment of neutrophils
contributes to disease progression by inducing inflammation, which leads to oxidative
stress and subsequent cell damage (Pease & Sabroe, 2002; Pease, 2006). Following acute
exposure to DEP, bronchial epithelial cells produced more IL-8 than control providing a
possible mechanism for the alteration of immune cell subsets in tissues exposed to
environmental toxins (Salvi et aI., 2000).

Interleukin 17
IL-17 is a pro-inflammatory cytokine, produced primarily from CD4+ T cells,
recognized to participate in certain inflammatory diseases. Specifically, IL-17 is central
to the initiation and pathogenesis of diseases such as asthma, psoriasis, RA, Crohn's
disease, and MS. This cytokine contributes to these disease both directly and indirectly,
as IL-17 may induce the production of other pro-inflammatory cytokines such as IL-6,
IL-8, and TNF-a (Wang & Liu, 2008). Additionally, IL-17 may contribute in the process
of angiogenesis, although through secondary mechanisms (Kindt, Goldsby, & Osborne,
2007). Despite the previously mentioned role as a pro-inflammatory mediator, IL-17
may have dual functions. Initial studies in IL-17 knockout mice showed that IL-17 was
required for the development of asthma in a murine model. However, experiments where
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IL-17 was neutralized during the effector phase of asthma, where an asthma model
system was already established, resulted in increased disease progression (SchnyderCandrian et aI., 2006). Therefore the role of IL-17 in inflammatory diseases needs to be
further investigated, especially in the context of asthma where this cytokine exhibits
pleiotropic effects.

Asthma

Asthma is a multifaceted disorder, with a recognized immunopathogological
component, represents a significant obstacle facing individuals, researchers, and
healthcare professionals in our contemporary society. While current research has yielded
an increased understanding of asthma with improved medicinal efficacy, the incidence
and severity of asthma continues to rise in both adults and children worldwide at an
alarming rate (Clement, Jones, & Cole, 2008; Dietert & Zelikoff, 2008). Despite this
increased body of knowledge, the exact factors responsible for the observed increase in
asthma prevalence, morbidity, and mortality remain unknown. According to the Center
for Disease Control Asthma Surveillance Summary, the estimated number of U.S.
citizens reporting an asthma episode in the previous 12 months increased from 6.8
million in 1980 (3.1%) to 14.9 million (5.6%) in 1995 (Martinez, 2008). It is estimated
that more than 300 million individuals and greater than 20% of the developed world
suffer from asthma-related symptoms with an estimated American 5,000 deaths per year
(Takhar et aI., 2007). Recent data analysis suggests that the rise in asthma may be
stabilizing; however disparities are evident when looking at factors such as age, race, sex,
and socio-economic class (Moorman et aI., 2007). In the context of childhood diseases,
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asthma is the most common chronic disease affecting children in the U.S. today (Center
for Disease Control, 2003). In terms of economic burden, it is estimated that the annual
cost of asthma is greater than 16 billion dollars, which factors in both cost of health care
and loss in productivity (Gergen, 2001).
Asthma is a complex inflammatory disease characterized by physiological
changes in the airway. These changes include an increase in smooth muscle mass, airway
hyperresponsiveness, decreased air flow, and an increase in size and number of mucosal
glands resulting in a thickened basement membrane (Ramos-Barbon, Presley, Hamid,
Fixman, & Martin, 2005; Munakata, 2006). Key hallmarks of asthma include eosinophil
infiltration, activation of T cells, inflammatory cytokine production, and local IgE
synthesis in bronchial mucosa (Kay, 2006). Current understanding of disease
pathophysiology recognizes that asthma is a chronic condition with activated helper T
(TH) cells facilitating disease progression. As allergens are inhaled and encountered in
the airways, APCs process and present Ag to other immune cells (Smit & Lukacs, 2006).
This process provides key signals that activate TH cells, which begin to produce cytokines
that drive TH2 type responses such as IL-3, IL-4, IL-5, and IL-13 (Kay, 2006). The
increase in TH2 cytokine production is paralleled by a decrease in THI cytokines (N goc,
Gold, Tzianabos, Weiss, & Celedon, 2005). Specifically, activated T cells are thought to
be the prominent cell type in chronic asthma and disease severity is positively correlated
with activated T H2 cell count (Kay, 2006; Holgate, 2008). These cytokines affect other
cells types such as B cells and eosinophils, which are integral in asthma pathogenesis by
production of IgE antibody and release of granular proteins, respectively (Holgate, 2008).
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Other cell types such as mast cells, monocytes, macrophages, and basophils are also
affected by T H2 cytokines further enhancing disease processes.

Beta-Adrenergic Receptor Agonists and Adverse Effects in Asthma
As the understanding of asthma pathogenesis continues to increase, so has the
usage of beta (p)-adrenergic agonist medications. The mechanism of action of this very
commonly used class of medication begins by binding to p-adrenergic receptors, a
protype member of the "seven pass membrane" family of proteins that is widely
distributed in the respiratory tract and to a lesser extent in cardiac and adipose tissue
(Johnson, 2006). This family of receptors, known as the G-protein-linked receptors, may
exist in two conformational states; active and inactive. While in the inactive
conformation, the p-adrenergic receptor is bound to the three subunits of the G protein

(a, p, and y) in a complex bound to guanosine diphosphate (118). When p-adrenergic
agonists (p-agonists), or associated ligands such as glucagon or epinephrine, bind to the
receptor, a conformational change is induced producing an activated a subunit through
the process of exchanging guanosine diphosphate for guanosine triphosphate (Benovic,
2002). This allows the activated a subunit to disassociate from the py complex and
initiate a signaling cascade, producing dramatic changes within the cell due to the action
of second messengers (Benovic, 2002; Houslay & Kolch, 2000). While IP 3 , Ca2+, G
proteins, and adenylyl cyclase are all activated through this pathway; the mechanism of
p-agonist medications is thought to involve the conversion of adenosine triphosphate to
cyclic adenosine monophosphate (cyclic AMP, cAMP) by adenylyl cyclase (Kindt,
Goldsby, & Osborne, 2007; Rot & von Andrian, 2004). While the exact mechanism of
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cAMP signaling has not been completely elucidated, it is thought to involve the action of
protein kinase A (PKA), a tetramer consisting of two regulatory and two catalytic units
(Tasken & Aandahl, 2004). The activated catalytic subunits act on target proteins
distributed throughout almost all mammalian tissues. In the context of asthma, the end
result is relaxation of airway musculature, alleviating asthma symptoms through airway
muscle relaxation producing bronchodilation (Newhouse & Dolovich, 1986).
The utilization of p-adrenergic agonist therapeutic properties to alleviate airway
constriction is not a new concept. Earliest historical record finds that these medications
were used in ancient Chinese herbal medicines to relieve breathing difficulties as early as
3000 BC. The active material, known as Ma Huang, was a plant derived alkaloid now
identified as ephedrine, which was not introduced into Western medicine until the 1920' s
(Sakula, 1986; Sears & Lotvall, 2005). As an understanding of p-adrenergic agonists has
advanced, improved second generation medications have been developed that are
currently divided into short lasting (4 - 6 h) and long lasting (10 - 12 h) bronchodilators,
which represent the most commonly prescribed types of asthma medication utilized today
(Johnson, 2006; Salpeter, Buckley, Ormiston, & Salpeter, 2006). While these
medications are popular among physicians and patients, the use of long acting p-agonists
has been controversial for more than 50 years (Fahy & Boushey, 1995). As evidence
accumulated on the potentially life-threatening and deadly p-agonist related events, it was
concluded that while the initial result of p-agonist therapy is beneficial for relieving
asthma symptoms, usage of these medications was possibly contributing to a worsening
of disease and lack of disease control. Therefore, the FDA launched the Salmeterol®
Multicenter Asthma Research Trial in order to delineate a direct relationship between
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long-acting p-agonists and severe asthma exacerbations and death (Salpeter, Buckley,
Ormiston, & Sal peter, 2006). This large scale study found a significant increase in the
rate of asthma episodes requiring medical intervention and asthma-related deaths in the
cohort receiving long acting p-agonist therapy, as compared to other asthma medications
(Nelson, Weiss, Bleecker, Yancey, & Dorinsky, 2006). Based on these findings, a "black
box" warning label has been implemented for this medication and is now recommended
that p-agonists be restricted for individuals whose asthma is not controlled via other
medicinal intervention (Salpeter, Buckley, Ormiston, & Salpeter, 2006). How p-agonists
therapy contributes to asthma pathogenesis remains to be determined but several theories
exist: tolerance of p-adrenergic agonist receptors to the medication, genetic variability,
and that this class of medication may mask the underlying inflammatory processes
(Wechsler et aI., 2006; Salpeter, Buckley, Ormiston, & Salpeter, 2006). One finding
from our lab indicates that the increase in asthma severity, morbidity, and mortality may
involve the effect of cAMP modulating p-agonists on the expression of CD40L.
Specifically, increases in intracellular cAMP in T cell receptor (TCR) activated T cells
can cause a further increase the level of CD40L expression in asthmatics while
downregulating expression in similarly activated cells from control subjects, (Wingett &
Nielson, 2002; Wingett & Nielson, 2003; Wingett, Forcier, & Nielson, 1999). As the
mechanisms of long-acting p-agonists are elucidated, therapies are being developed to
maximize the therapeutic effects while minimizing the associated side effects.
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Negative Health Effects of Diesel Exhaust Particles
While the biological effects ofDEP exposure on the respiratory system can be
manifested by coughing, wheezing, and bronchitis, life-threatening respiratory events
involving decreased lung function, chronic obstructive pulmonary disease, inflammation,
and asthma attacks can occur resulting in an elevated rate of hospital admissions for
respiratory distress (Eder, Ege, & von Mutius, 2006; Tatum & Shapiro, 2005; Pope, III &
Dockery, 2006; Hesterberg et aI., 2009; Maier et aI., 2008). In addition to the respiratory
system, DEP can affect a multitude of organ systems. Epidemiological, in vitro, and in

vivo studies demonstrate DEP to be a potential carcinogen with lung cancer
predominantly manifested, with bladder and lymphatic tissues cancers occurring less
frequently following occupational exposure (Ris, 2007; Lewtas, 2007). Acute and
chronic exposure to DEP has also been linked to increased cardiac-related morbidity and
mortality with recent attention focused on the contribution of DEP in neurodegenerative
and other neurologic pathologies (Pope, III & Dockery, 2006; Ris, 2007; Hartz, Bauer,
Block, Hong, & Miller, 2008).

Diesel Exhaust and Asthma
Epidemiological studies demonstrate a positive relationship between decreasing
air quality and the rate of asthma exacerbations, especially those requiring medical
intervention (Holguin, 2008). In addition to the change in exacerbation rate, the severity
of these events is increased, resulting in an amplified asthma related morbidity and
mortality, especially in children (Pandya, Solomon, Kinner, & Balmes, 2002; Riedl &
Diaz-Sanchez, 2005; Parker, Akinbami, & Woodruff, 2009; Kim et aI., 2008; Samuelsen,
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Nygaard, & Lovik, 2008). The underlying mechanism of these events is unknown but
studies have shown associations between the proximity to high traffic roadways,
especially mass transit routes such as freeways, and respiratory distress (LwebugaMukasa, Oyana, Thenappan, & Ayirookuzhi, 2004). Recent studies have linked trafficrelated PM with negative health effects by utilizing geographic information systems
technology to establish associations between major traffic ways and adverse health events
(Samuelsen, Nygaard, & Lovik, 2008; Annesi-Maesano et aI., 2007; McEntee & OgnevaHimmelberger, 2008). Additionally, the increased medical intervention in children has
been linked to living near major roadways versus suburban locations (Morgenstern et aI.,
2007). A recent large scale national study on respiratory stress in children confirmed this
relationship as individuals living within 20 miles from EPA pollution monitoring stations
that had increased levels ofPM2 .5 were more likely to experience adverse respiratory
events (Parker, Akinbami, & Woodruff, 2009).
In addition to the epidemiological studies, in vivo and in vitro analyses confirm a
role for air pollution, specifically diesel exhaust, in asthma exacerbations. Some of these
studies implicate that the deleterious effects observed for respiratory health may involve
an inflammatory component as DEP exposure is linked to asthma exacerbations and
increased asthma-related morbidity and mortality, known to be partially immune-related
(Holgate, 2008; Mitschik, Schierl, Nowak, & Jorres, 2008). While the inhalation of PM
can act as a direct respiratory irritant, the carbon core ofDEP can bind allergens and
toxins from the environment further enhancing DEP-related toxicity (Hesterberg et aI.,

2009). In vitro and in vivo studies have shown DEP exposure to contribute to asthma
pathogenesis via increased allergen-specific IgE, production of asthma-associated
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cytokines, and increased airway hyperresponsiveness (Inadera, 2006; Nel, Diaz-Sanchez,
Ng, Hiura, & Saxon, 1998). Specifically, allergen sensitive individuals exposed to
ragweed pollen plus DEP produced significantly more allergen-specific IgE (l6-fold
greater) in comparison to DEP alone, identifying DEP as a possible immune system
adjuvant (Diaz-Sanchez, 1997). Animal studies further support the adjuvant capacity of
DEP as allergen-associated inflammation was further heightened when DEP treatment
was combined with model allergens such as ovalbumin or lipopolysaccharide (Ris, 2007;
Inadera, 2006). Human controlled-exposure studies using short term exposures to DEP
show that exposure can alter immune cell distribution in bronchalveolar lavage fluid and
bronchial biopsies such as neutrophils, mast cells, CD4+ T cells, CD8+ T cells, B cells,
and platelets, in addition to increasing neutrophils in sputum samples (Salvi et aI., 1999).
The alteration of immune cell subsets and the adjuvant role of DEP implicates this
environmental pollutant as a key contributor to the pathogenesis of asthma and other
allergic diseases. Despite these advances in knowledge, it still unclear how DEP
modulate T cell function by altering activation, distribution, and cytokine production in
TH cells. One of the goals of the present study is to further advance the field ofDEP
research by addressing this gap in knowledge.

Diesel Exhaust, Immune Cells, & Inflammatory Cytokines
While it is accepted that DEP are a health hazard, the exact mechanisms of action
for these particles in the living organism remain unclear. Studies conducted on airway
epithelial cells in vitro demonstrate many different affects. While these studies are hard
to compare as experimental conditions vary, the main point of these studies is that
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inhalation of diesel exhaust particles can alter normal epithelial cell function (Mitschik,
Schier!, Nowak, & J orres, 2008). Other studies have focused on the ability of DEP to
alter cytokines, which contribute to asthma pathogenesis. Specifically, the TH2 family of
cytokines is of interest as these cytokines are associated with asthma pathogenesis. DEP
exposure to both human and animal immune cells results in an increase in the expression
ofIL-4, IL-5, IL-13 and decrease the production ofIL-2 and IPN-y, which favors a TH2
cytokine environment (Mamessier, Nieves, Vervloet, & Magnan, 2006; Riedl & DiazSanchez, 2005; Ohtani et aI., 2005; Pourazar et aI., 2004; Takano, Yanagisawa, & Inoue,
2007; Samuelsen, Nygaard, & Lovik, 2008; Stevens, Cho, Linak, & Gilmour, 2009;
Gowdy et aI., 2008). In vitro studies further confirmed the role of TH2 cells by polarizing
peripheral blood mononuclear cells from healthy individuals towards either THI or TH2
phenotype and exposing the cells to DEP. Only the TH2 polarized cells had the ability to
undergo chemotaxis, allowing these cells to migrate to the site ofDEP exposure (Chang
et aI., 2006). Considering the role ofTH2 cells in asthma pathogenesis and the ability of
DEP to alter this balance, it is plausible that DEP can alter production of these cytokines
to favor TH2 type cell development and further promote asthma disease progression
providing a possible link to the epidemiological studies that demonstrate an association
between particulate matter levels and adverse respiratory events.
Based on the integral role of TH cells in the development and pathogenesis of
allergic disease, it is surprising to find a lack of research on the direct effects ofDEP
exposure on TH cell activity. The research presented in this study contributes to the body
of knowledge identifying DEP as a major health concern by showing in vitro evidence of
an immunomodulatory effect of DEP on T H cells. Specifically, DEP exposure alters the
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tightly regulated expression of CD40L with a consistent and preferential induction of the
membrane-bound isoform versus the less biologically active soluble form of the CD40L
protein. The ability ofDEP to augment CD40L expression, both soluble and membrane
forms, in the context of an in vitro asthma model is also reported, providing a mechanism
for the negative effects of DEP on at-risk individuals. Additionally, DEP exposure alters
production of an important imrnunomodulatory cytokine factor, IL-17, without having
any appreciable effect on T H cell viability. Collectively, these findings elucidate a
potential molecular mechanism for the deleterious effects of DEP exposure on TH cells,
as measured by changes in key parameters of immune system function.
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EXPERIMENTAL PROCEDURES
Diesel Particulate Matter
Diesel exhaust particles (DEP) SRM 2975 was purchased from the National
Institute of Standards and Technology (Gaithersburg, MD). These particles were
generated by a heavy-duty forklift diesel engine and collected using a filtering system
designed for diesel forklifts under "hot" conditions, without a dilution tunnel (Singh et
aI., 2004). Certified analyses for SRM 2975 are accessible online (National Institute of
Technology, 2000). DEP solutions were prepared in phosphate buffered saline (PBS) and
sonicated in a water bath for 15 min. Particles were vortexed immediately prior to
dispensing into each individual cell culture well.

Human Subjects and Isolation of CD4+ T Cells
Written, informed consent was obtained from all blood donors and the University
Institutional Review Board approved this study. For isolation of CD4+ T cells, peripheral
blood mononuclear cells (PBMC) were obtained via Ficoll-Hypaque (Histopaque-l0n,
Sigma, St Louis, MO) gradient centrifugation using heparinized phlebotomy samples as
previously described (Coligan, 1995). After removal of the leukocyte layer, cells were
washed three times with Hank's buffer (Sigma, S1. Louis, MO) and once in PBS. After
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isolation ofhwnan PBMC, CD4+ T cells were purified using negative immunomagnetic
selection per manufacturer's instructions using a cocktail of antibodies against CD8,
CD 14, CD 16, CD 19, CD56, and glycophorin A (StemCell Technologies, Vancouver,
BC) with collection of unlabeled T cells (typically >96% CD4+ and >98% viable as
assessed by flow cytometry). Purified CD4+ cells were subsequently cultured in RPMI1640 media (Sigma, St. Louis, MO) supplemented with 10% fetal calf serum (FCS), 100
U/ml penicillin, and 100 Ilg/ml streptomycin sulfate at 37°C and 5% CO 2.

T Cell Activation and Culture Conditions
Purified CD4+ cells were cultured in RPMIIl 0% FCS at 1 x 106 cells/rnl in 200 III
total volume and activated using immobilized anti-CD3 Ab (OKT3, ATCC, Rockville,
MD) at 0.24 Ilg/well or anti-CD3/anti-CD28 beads (Dynabeads® CD3/CD28 T Cell
Expander, Invitrogen, Oslo, Norway) at a 1: 1 bead to cell ratio in 96-well tissue culture
plates (Fisher Scientific, Pittsburg, PA). Alternate activation schemes involved treating
purified CD4+ T cells with various combinations of ionomycin (Calbiochem, San Diego,
CA), phorbolI2-myristate 13-Acetate (PMA, Sigma), and/or 100 11M dibutyryl
adenosine monophosphate (dbcAMP, Sigma) was utilized in combination with
ionomycin. Cultures were concurrently treated with varying concentrations of freshly
prepared and sonicated DEP for 24 h of culture.

Antibodies and Flow Cytometry
Methods of immunofluorescent staining and flow cytometry were performed as
previously described (Coligan, 1995). Briefly, cells were harvested from 96-well culture
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plates into F ACS buffer and pelleted by centrifuged at 2000 rpm for 7 min. The cell
pellet was resuspended in FACS buffer and stained with fluorescently labeled antibodies
for 30 min at 4°C, washed two times, fixed in 2% paraformaldehyde, and analyzed on a
4-color Epics flow cytometer (Beckman Coulter, Miami, FL). Ten thousand events gated
on size and side scatter were analyzed and the expression of the percentage of positively
staining cells or the mean fluorescence intensity (MFI) determined by comparisons to
appropriate isotype controls. Phycoerythrin (PE) or fluorescein isothiocyanate (FITC)conjugated anti-CD40L, anti-CD69, anti-CD25, or isotype control antibodies were
purchased from Beckman Coulter or BD Biosciences (San Jose, CA). Appropriate
concentrations of each Ab were determined by titration for optimal staining prior to
experimental use.

Cell Viability Assay
To assess the effect of DEP on CD4+T cell viability, propidium iodide (PI)
staining was employed. Purified T cells were treated with increasing concentrations of
DEP (0-800 Ilglml) for 24 h. Cell viability was determined by staining with 50 Ilg/ml of
PI, a fluorogenic dye used to monitor losses in cell membrane integrity, for 10 min prior
to flow cytometric analysis.

Enzyme-Linked Immunosorbent Assay
Levels of soluble CD40L (sCD40L) in culture supernatants was quantified using
an enzyme-linked immunosorbent assay (ELISA). CD4+ T cells were treated with
various cell specific stimuli, as described above, for 24 h. Following incubation, cell-free
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supernatant was harvested via successive 10 min centrifugations (2,000 rpm, 7,000 rpm
and 13,000 rpm) and cell supernatants stored at -80°C until analysis. A 96-well plate
(Nunc-Immuno Module, Nunc, Rochester, NY) was coated with 50 III of TRAP-l
monoclonal Ab (R & D Systems, Minneapolis, MN) at 12 Ilglml in 0.05 M carbonate
buffer (pH 9.4) and incubated for 2 h at 37°C. Wells were blocked with 10% FCS/2%
azide in PBS and incubated at room temperature (RT) for 2 h. Samples (50 Ill/well) were
added to the plate and incubated overnight at 4°C. Serial dilutions of recombinant human
sCD40L protein standard (Bender Medsystems, Burlingame, CA) were used for
standardization. Bound sCD40L was detected using 50 Ill/well HRP-conjugated M90
mAb (ATCC, Manassas, V A) at 12 Ilglml in 10% FCS in PBS and incubated at RT for 2
h. The assay was developed with 3,3',5,5'-tetramethylbenzidine (TMB, Sigma) and
incubated at RT protected from light for 30 min. The reaction was stopped with 0.5 M
H2 S04 and optical density determined at 450 nm and reference wavelength at 630 nm, on
a microplate reader (Bio-Rad, Hercules, CA).
ELISA assays were also used to investigate the effect ofDEP treatment on IL-8
and IL-17 cytokine production using primary CD4+ T cells (5 x 106 cells/ml) treated with
anti-CD3/anti-CD28 Dynabeads® (200 beads/ml) for 24 h ± DEP. Following DEP
treatment, cell-free supernatant was harvested via successive 10 min centrifugations
(2,000 rpm, 7,000 rpm and 13,000 rpm) and cell supernatants stored at -80°C until
analysis. ELISA assay was performed by the UMAB Cytokine Core Laboratory
(Baltimore, MD) with all samples analyzed in triplicate and cytokine production
expressed in pglml.
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In Vitro Cleavage of CD40 Ligand by Recombinant ADAM-tO
For in vitro CD40L cleavage assays, the murine CD40L/CD33 fusion protein was
used (R&D) which contains amino acids 61-260 of the extracellular CD40L domain
joined to the signal peptide of human CD33 followed by 10 histidine residues and a
linker peptide. The cleavage of 0.5
accomplished using 20

~g/ml

total reaction volume of 25

~g

of murine CD40L/CD33 fusion protein was

recombinant mouse ADAM-IO (R&D) for 5 h at 37°C in a

~1.

The cleavage products were separated by 10% sodium

dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE) under reducing conditions
and transferred to a polyvinylidene difluoride membrane utilizing a wet transfer system
(Bio-Rad Life Sciences Research, Hercules, CA). Detection was performed using an
anti-CDl54 C-20 polyclonal Ab (Santa Cruz Biotechnology, Santa Cruz, CA) followed
by a secondary goat anti-rabbit horseradish peroxidase-conjugated Ab (Santa Cruz) using
an enhanced chemiluminsence system (PerkinElmer Life Sciences, Boston, MA).

Data Analysis
Statistical significance was determined using either a two-way paired Student's Ttest or repeated measures analysis of variance (AN OVA) with post hoc comparisons. A
Student's T-test was utilized to determine the effect ofDEP treatment between treatments
in paired samples. A repeated measures ANOV A with post hoc comparisons was used
when two or more measurements of the same type were made on the same subject to
determine statistical differences between the means and to allow separation of withinsubject variation from between subject variation. ANOV A analysis was performed using
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SAS (Statistical Analysis Systems Incorporated) software (Cary, NC). Significance
levels were defined as p < 0.05.
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RESULTS
Effects of DEP on Resting T Cells
Although limited studies have demonstrated an immunomodulatory effect of
diesel exhaust particles (DEP) on select cell types and biological systems, additional
studies are needed to assess the role of DEP on normal TH cell function. To help address
this gap in knowledge, experiments were conducted to assess the effects ofDEP on the
expression of T cell activation markers in the absence of external stimuli. Purified
human peripheral blood CD4+ T cells were treated with 800 Ilglml DEP for 24 h and
expression of CD40L, CD69, and CD25 membrane proteins evaluated using flow
cytometry. As shown in Fig. 1, CD40L expression was markedly upregulated following
treatment with DEP with a 3.5-fold increase observed compared to control samples (p <
0.0001). A slight yet significant increase (1.5-fold) in CD69 expression was also
observed (p

=

0.037), although to a considerably lesser extent than CD40L. In addition,

an increasing trend for CD25 was also observed (1.1-fold), although this did not achieve
statistical significance (p

=

0.068). These results indicate that DEP can alter helper T cell

activation in resting cells, with the most pronounced effects observed for CD40L
expressIOn.
Additional studies were performed to verify that DEP-induced CD40L expression
occurred in a concentration-dependent manner. Purified T cells were treated with
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increasing concentrations ofDEP (200 - 800 Ilg/ml) for 24 h and evaluated using flow
cytometry. As shown in Fig. 2, a reproducible 1.7-fold increase in membrane CD40L
expression was observed at the lowest concentration ofDEP (200 Ilg/ml), although
statistical significance was not achieved in these samples (p = 0.11). In contrast, DEP
induced significant increases in CD40L expression at both 400 Ilg/ml ofDEP (2.5-fold
increase,p = 0.03) and at 800 Ilg/ml (3.5-fold increase,p = <0.0001). Higher
concentrations ofDEP (i.e. 1600 Ilg/ml) induced similar levels ofCD40L compared to
that observed with 800 Ilg/ml DEP (data not shown).

DEP Augments Physiological Activation of T Cells

Additional studies were performed to evaluate the effects ofDEP on activated T
cells using a variety of physiologically relevant activation schemes. The first set of
experiments were designed to assess the immunomodulatory effects ofDEP on cells
previously activated through the T cell receptor (TCR) signaling pathway using
antibodies directed against the CD3 component of the TCR to mimic the potential effects
ofDEP exposure in patients with low-level immune cell activation that can accompany
chronic inflammatory disease. Purified CD4+ T cells were pre-treated with immobilized
anti-CD3 Ab for 6 h, removed from activation stimuli and subsequently treated with DEP
for 18 h. Cells were then evaluated for changes in T cell activation markers using flow
cytometry. Notably, a modest, yet reproducible and statistically significant increase in
DEP-induced CD40L expression (1.5-fold,p = 0.03) was observed, Fig. 3A. In contrast,
neither CD69 nor CD25 expression (Figs. 3B and 3C) was induced by DEP exposure
using this activation scheme (p = 0.81 and 0.11, respectively).
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The effects ofDEP were next investigated using T cell stimuli consisting of
combined activation through the TCR signaling pathway and CD28 costimulation. The
CD28 costimulatory pathway plays a major role in T cell activation by lowering the
activation threshold, or the number of bound TCRs required to achieve activation, by ~8fold (Salomon & Bluestone, 2001; Lanzavecchia, Lezzi, & Viola, 1999). To
simultaneously provide both signals important for T cell activation, polystyrene beads
with covalently linked anti-CD3 and anti-CD28 antibodies (Dynabeads®) were used to
optimally activate CD4+ T cells. This activation scenario utilizing beads of similar size to
lymphocytes is recognized to better mimic the physiological conditions occurring during
antigen presentation between T cells and APC than activation using plate-immobilized
antibodies (Trickett & K wan, 2003). Following 24 h of culture, T cell activation markers
were evaluated using flow cytometry. DEP was found to significantly augment (1.2-fold,
p = 0.03) the expression of CD40L protein (Fig. 4). In contrast, a decreasing trend in

CD69 expression was observed following DEP treatment (1.2-fold,p

= 0.68) and a slight,

yet insignificant, increase in CD25 was observed (l.I-fold, p = 0.18). Collectively, these
findings suggest potentially unique actions ofDEP to consistently enhance CD40L
expression in both resting T cells, as well as in the presence of different activation
stimuli.

DEP Plus PKC Signaling Results in Increased T Cell CD40L
Based on the observation that CD40L expression is increased in response to DEP
exposure in TCR activated cells, experiments were performed to dissect TCR signal
transduction events into the component calcium and protein kinase C (PKC) dependent
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pathways. The PKC pathway was isolated using the phorbol ester, PMA, which is well
recognized as a chemical initiator of PKC-dependent signal transduction in T cells (Ding,
Green, Thompson, & Shevach, 1995). For these studies, primary CD4+ T cells were
concurrently treated with PMA and DEP for 24 h, and changes in expression of CD40L,
CD69, and CD25 measured using flow cytometry. As shown in Fig. 5A, DEP was found
to induce CD40L expression (3.5-fold,p < 0.0001). In contrast, no effects on CD25 or
CD69 expression were observed at this particular concentration of PMA, which induced
near maximal expression ofthese proteins (data not shown). In order to reveal any
possible actions ofDEP to modulate CD25 and CD69 expression, a lower concentration
of PMA was used. As shown in Fig. 5B and 5C, DEP caused a modest reduction in
CD25 expression (1.3-fold,p = 0.05), while no effects on the percentage ofCD69
positive cells were discemable, which could be related to the fact that the very low
concentration of PMA used in these experiments still induced near maximal levels of
CD69 expression. However, the mean fluorescence intensity (MFI) of CD69 was
decreased by DEP (1.3-fold;p = 0.008; MFI values of 299.2 ± 1.7 vs. 230.2 ± 7.8).
Therefore, the ability of DEP to augment PKC---dependent signaling may be relatively
unique to CD40L as either the percentage of positively staining cells or the MFI of CD25
and CD69 was reduced by DEP.
Further dissection of the TCR signaling pathway was achieved using the calcium
ionophore, ionomycin, to activate calcium-dependent signaling as commonly described
(Nusslein et aI., 1996; Chatila, Silverman, Miller, & Geha, 1989). Primary CD4+ T cells
were treated with ionomycin in the presence ofDEP for 24 h and changes in membrane
expression of CD40L, CD69, and CD25 evaluated. As shown in Fig. 6A, DEP plus
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calcium ionophore produced modest but consistent increases in CD40L expression (1.3fold,p = 0.03), although not to the extent of PMA activated samples (Fig. 5A). In
contrast, a slight, yet significant, DEP-induced decrease (1. I-fold, p = 0.004) in CD25
expression was observed (Fig. 6B). As shown in Fig. 6C, no effects ofDEP on the
percentage of CD69 positive cells were discemable, but again this could be related to the
fact that near maximal expression of this protein was induced by ionomycin.
Nevertheless, a significant 2.1-fold decrease in the MFI of CD69 (144.8 ± 2.6 to 70.7 ±
7.3) was again observed following treatment with DEP,p = 0.011, indicating yet another
circumstance where CD40L expression appears to be preferentially induced by DEP
relative to the other activation markers studied.
Additional studies were performed to evaluate the effects ofDEP in cells
activated by both calcium- and PKC-dependent signaling pathways. As the combined
treatment of PMA and Ca2+ can frequently result in the synergistic and maximal
expression of CD40L (Chatila, Silverman, Miller, & Geha, 1989), lower concentrations
of these physiological agents were utilized for these experiments. As shown in Fig. 7, at
both of the lower concentrations of PMA and ionomycin tested, a slight yet significant
induction ofCD40L was observed following DEP exposure (1.5-fold in 0.125 11M
ion/O.30 ng/ml PMA and a 1. I-fold in 0.25 11M ion/O.67 ng/ml PMA activated cells, p <
0.0001 and p = 0.017, respectively). No measurable induction of CD40L was noted at
the highest concentrations of PMNIonomycin used, but this is not unexpected as these
concentrations of mitogens induced near maximal levels of CD40L on their own. As
both PKC and calcium pathways are involved in TCR signaling, the results obtained from
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these studies are consistent with those presented in Fig. 3, where DEP also induced
CD40L expression in CD3/TCR activated cells.

DEP Differentially Regulates the Expression of Membrane and Soluble CD40L
Based on the observation that membrane CD40L expression is induced by DEP,
experiments were performed to evaluate the effects ofDEP on the expression of the
soluble form of the CD40L protein (sCD40L), which also has biological activity and can
function in a cytokine-context by distribution throughout the body. As previously shown
by our lab, the membrane and soluble forms of the CD40L protein can be differentially
regulated by the PKC and Ca2+ pathways, with sCD40L being preferentially produced
following PKC signaling (Matthies, Newman, Hodzic, & Wingett, 2006). Following 24
h ofDEPIPMA exposure, cells were concurrently evaluated for membrane CD40L and
sCD40L by flow cytometry and ELISA as shown in Fig. 8A & B. In contrast to the DEPinduced increase in membrane CD40L (2.7-fold,p = 0.005), the production ofsCD40L
was not altered following DEP exposure in the absence of external stimuli (p = 0.11). In
samples activated with PMA and DEP, and consistent with our previous experiments
(Fig. 5), membrane CD40L expression was increased (3.5-fold,p < 0.0001) by DEP as
shown in Fig. 8A. In marked contrast, sCD40L levels were reduced by 2.4-fold
following DEP treatment, (Fig. 8B,p = 0.04).
In parallel experiments, the effects of DEP to alter sCD40Llmembrane CD40L
expression in ionomycin activated cells were evaluated. As shown in Fig. 8C, DEP
induced the expected increase (1.3-fold, p = 0.004) in membrane CD40L expression in
ionomycin activated cells. In contrast, DEP failed to appreciably affect sCD40L
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expression in ionomycin-activated cultures (Fig. 8D, p = 0.48). Collectively, the results
presented in Fig. 8 indicate that the membrane and soluble forms of the CD40L protein
can be differentially regulated by DEP.
To further investigate the ability ofDEP to polarize CD40L expression towards
the membrane-bound form, experimental conditions combining ionomycin and PMA to
mimic the calcium and PKC signaling pathways accompanying T cell receptor ligation
(Chatila, Silverman, Miller, & Geha, 1989), as well as direct TCR activation using antiCD3 and CD28 antibodies were used. As shown in Fig. 9A, following 24 h of
PMAIionomycin activation, sCD40L expression was decreased by an ~ 1.3-fold, p =
0.018. In parallel experiments involving CD3 (TCR)/CD28 antibodies linked to
polystyrene Dynabeads®, DEP was also shown to produce a significant decrease (1.6fold,p = 0.04) in sCD40L expression (Fig. 9B). The effects ofDEP to enhance the
production of membrane CD40L in both PMAIionomycin and anti-CD3/CD28 activated
cells was shown previously (see Fig. 4 and 7). These finding indicate the ability ofDEP
to preferentially induce the membrane form of the CD40L protein relative to the soluble
protein.

Effects ofDEP on ADAM-tO Mediated Proteolytic Cleavage ofCD40L
Given that DEP has different regulatory effects on the production of membrane
and soluble CD40L protein forms, experiments were performed to gain insights into the
mechanisms ofDEP action. It has been recently been reported that stimuli leading to the
differential production of membrane or soluble CD40L proteins can involve the action of
matrix metalloproteinases, including ADAM-lO (Matthies, Newman, Hodzic, & Wingett,
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2006; Jin et aI., 2001). This protease has been implicated in the process of ectodomain
shedding, a process integral for the production of numerous soluble factors including
Beta-amyloid precursor protein, Notch, CXCL13, and Type IV collagen (Parkin &
Harris, 2009; Abel et aI., 2004; Millichip, Dallas, Wu, Dale, & McKie, 1998; Tian et aI.,
2008). Most relevant to this study, ADAM-lO has been shown to contribute to the
production ofT cell-derived sCD40L by generating this smaller protein product via
cleavage from the full-length membrane-bound CD40L precursor molecule (Matthies,
Newman, Hodzic, & Wingett, 2006). In the present study, experiments were performed
to determine whether the preferential production of membrane CD40L relative to
sCD40L occurred by actions ofDEP to inhibit ADAM-10-mediated cleavage of the fulllength protein. Recombinant ADAM-lO enzyme was incubated with a murine CD40L
fusion protein (32 kDa), the mixture fractionated by SDS-PAGE, and Western blotting
performed to detect the sCD40L product. As shown in Fig. 10, in a control sample
containing the purified CD40L fusion protein, only a single band of ~32 kDa
corresponding to the full-length membrane form of CD40L was observed (Lane 1).
Likewise, in a control containing the murine CD40L fusion protein and DEP, only the 32
kDa band was detected (Lane 2). The addition of the ADAM-10 protease to the CD40L
fusion protein resulted in the generation of an ~ 18 kDa fragment corresponding to
sCD40L, and another band of ~ 9 kDa, as shown in Lane 3. The 18 kDa band has been
previously described by multiple labs (Graf et aI., 1995; Ludewig, Henn, Schroder, Graf,
& Kroczek, 1996; Matthies, Newman, Hodzic, & Wingett, 2006; Mazzei et aI., 1995),

while the 9 kDa cleavage product likely represents an additional cleavage event by
ADAM-1 0 that is detected by the polyclonal antibody used in our studies. Of interest,
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DEP increased the abundance of the 18 kDa band, while markedly decreasing the
intensity of9 kDa band (Lane 4). Although somewhat contrary to the initial hypothesis,
these results indicate that DEP can alter the activity of ADAM-l 0 to proteolytically
process the CD40L protein. This is indicated by the ability ofDEP to block the
production of the 9 kDa fragment and concurrently increase the 18 kDa product, leading
to a slight overall increase in the level of sCD40L in this cell-free system. It should also
be noted that slightly lower levels of full-length 32 kDa CD40L protein appear in both
samples containing DEP. This is likely due to the presence of very high molecular
weight aggregates containing DEP-absorbed CD40L fusion protein, interfering with some
of the loaded protein's ability to migrate into the gel matrix. Nevertheless, our results
indicate that the presence of DEP can alter the proteolytic activity of ADAM-l 0 cleavage
of CD40L, leading to an increase in the 18 kDa product, known as sCD40L, while
simulataneously preventing the formation of a smaller 9 kDa CD40L-derived fragment.

IL-17, Not IL-8, Production Is Decreased Following DEP Exposure
To further investigate the effects ofDEP on T cell activation processes, changes
in the expression of two T cell cytokines, IL-8 and IL-17, were evaluated. Both of these
cytokines are considered to be proinflammatory factors, where their altered expression
has been implicated in the pathogenesis of various inflammatory disease, including
asthma (Hashimoto, Akiyama, Kobayashi, & Mori, 2005; Pease & Sabroe, 2002). CD4+
T cells were activated using soluble anti-CD3/CD28 Dynabeads® and concurrently
treated with DEP. Following 24 h, cell free supernatants were harvested and evaluated
by ELISA. As shown in Fig. 11, DEP was found to inhibit the production of IL-17 by
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2.9-fold in comparison to control cells,p = 0.04. In contrast, DEP had no significant
effect on IL-8 production following treatment with DEP (p

=

0.28). The DEP-induced

decrease in IL-17 generation may be relevant to allergic diseases, or other conditions
involving an immune component as this cytokine, while considered a pro inflammatory
cytokine, exhibits pleiotropic effects and may actually be beneficial in the amelioration of
certain diseases (Schnyder-Candrian et aI., 2006; Miossec, 2009). Further research is
needed to elucidate the implications of IL-17 inhibition in the context of asthma and other
allergic diseases.

T Cell Viability Is Not Altered Following DEP Exposure
Based on our findings that DEP may have immunomodulatory effects capable of
altering cytokine production and the expression of certain T cell activation markers,
experiments were performed to evaluate the extent to which DEP potentially affects T
cell viability. Resting purified CD4+ cells were treated with increasing concentrations of
DEP (0-800 Ilg/ml) for 24 h and effects on viability determined using propidium iodine
(PI) staining and flow cytometry. PI is a red fluorescent nuclear stain that enters only
cells with disrupted plasma membranes, a characteristic utilized as an indicator of cell
death (Riccardi & Nicoletti, 2006). As shown in Fig. 12, no measurable effects ofDEP
on T cell viability were observed using identical experimental conditions in which
significant enhancement of CD40L was detected.
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DEP Augments Cyclic AMP-induced Membrane and Soluble CD40L Expression
As mentioned previously, the ability ofDEP to augment immune cell function has
been implicated in the increase in asthma prevalence in developed countries (Kagawa,
2002). Our observation that DEP can induce T cell CD40L expression under a variety of
relevant activation stimuli (Figs. 1-7) led us to examine the contributions that alterations
in cyclic AMP (cAMP) may exert, given that actions of the most commonly prescribed
class of asthma medications,

~-adrenergic

agonists, function to increase intracellular

cAMP. Despite its well recognized immunosuppressive role, cAMP has been recently
recognized to have certain pro-inflammatory properties. For example, dbcAMP, a cell
permeable analog of cAMP, has been shown to markedly increase T cell CD40L
expression, especially in cells activated with calcium ionophore or costimulated to
increase their intracellular calcium levels (Wingett, Forcier, & Nielson, 1999).
Therefore, we investigated whether the combined treatment of cAMP and DEP leads to a
greater, or possibly even synergistic, induction of T cell CD40L expression. For these
experiments, purified cells were treated with ionomycin or ionomycin and dbcAMP, and
concurrently treated with DEP or vehicle control. After 24 h of culture, CD40L was
measured using flow cytometry. As previously reported, treatment with db cAMP in the
absence of external physiological stimuli failed to appreciably affect CD40L expression
(Nielson & Wingett, 2002). DEP in the absence of external stimuli resulted in a
significant increase in membrane CD40L (3 . I-fold, p = 0.005), further validating the
immunomodulatory effect shown in Figs. lA and 2. Also as expected (Wingett, Forcier,
& Nielson, 1999), calcium ionophore alone was sufficient to induce moderate levels of

CD40L, while the addition of db cAMP resulted in even greater CD40L expression (1.7-
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fold). Of interest, the combination ofDEP plus dbcAMP plus ionomycin lead to the
greatest induction of membrane CD40L that was 1.2-fold higher than cells treated with
ionomycin and dbcAMP alone, p

=

0.002.

With regards to sCD40L expression, treatment with DEP alone had no effect on
sCD40L. However, the 3-way combination ofDEP plus dbcAMP plus ionomycin lead to
a marked increase (l.9-fold) in sCD40L compared to ionomycin plus dbcAMP controls
(Fig. 13B,p = 0.0004). This finding is notable as only in this context has DEP been
shown to increase sCD40L production, which could be very relevant to asthmatics who
are commonly prescribed cAMP-inducing asthma medications. However, in contrast to
membrane expression, DEP in the absence of stimuli was insufficient to induce sCD40L
production. In the instance where p-agonists, DEP or other emission-based
environmental pollutants, and low levels of chronically activated T cells exist (i.e.
chronic asthmatics using beta-agonists in industrialized areas), this trifecta could lead to
elevated circulating levels of membrane and biologically active sCD40L, which could
mechanistically contribute towards asthma exacerbations associated with DEP exposure.
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DISCUSSION
Diesel exhaust particles (DEP) represent a noteworthy and complex
environmental health concern with extensive evidence accumulating to support a causal
relationship between DEP and deleterious health impacts. Epidemiologic studies have
linked high levels of ambient PM pollution to increased hospital admissions, morbidity
and mortality for cardiovascular, neurological and pulmonary events (Pope, III &
Dockery, 2006; Ris, 2007; Hesterberg et aI., 2009; Maier et aI., 2008). Current
understanding of DEP suggests it possesses immunoregulatory properties altering
immune system function, potentially contributing to the observed increase in lifethreatening events following PM exposure. As activated T cells are important immune
cells involved in the pathogenesis of the aforementioned conditions, experiments were
performed to clarify the role of DEP on healthy T cell function, specifically the helper T
cell subset.
Helper T (TH) cells are integral regulators of immune system function and
activation is tightly regulated. The data presented in this study provides evidence of an
immunomodulatory effect ofDEP as measured by the alteration ofTH cell activation by
increasing the expression of T cell activation marker, CD40L (Fig. 1). The ability of
DEP to induce CD40L expression may be very relevant to allergic disorders as
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expression of this protein, primarily from activated T cells, is transiently expressed with
peak expression occurring 3-6 h after activation (Roy, Waldschmidt, Aruffo, Ledbetter,
& Noelle, 1993). While a small enhancement of CD69 and CD25 expression was also

observed, it was to a lesser extent (Fig. 1), accounting for a potential ability of DEP to
exacerbate allergic and inflammatory-based diseases, especially those involving altered
CD40L expression (Pandya, Solomon, Kinner, & Balmes, 2002). In addition, CD40L is
essential to proper immune function, as inappropriate expression may contribute to the
pathogenesis of disorders such as SLE, diabetes, and MS (Schonbeck & Libby, 2001; Xu
& Song. 2004). To further validate the effects ofDEP on CD40L expression, a scheme

was utilized to mimic the effects of DEP exposure where individuals may be exposed to
greater levels of DEP as a result of occupational exposure or housing location. A modest,
yet dose-dependent induction of CD40L following DEP exposure was observed (Fig. 2),
suggesting that individuals living in proximity to emission sources or those with an
occupational exposure may be at higher risk for the deleterious effects ofDEP
(Samuelsen, Nygaard, & Lovik, 2008; Annesi-Maesano et aI., 2007; McEntee & OgnevaHimmelberger, 2008). The ability ofDEP to alter CD40L expression in the absence ofT
cell specific stimuli is concerning as even small changes can have significant biological
effects given that a 1.1 to 2.0 fold increase in CD40L can result in a 4-5 fold increase in
B cell antibody (Ab) production and a similar increase in B cell proliferation and
monocyte matrix metalloproteinase production (Perez-Melgosa, Hollenbaugh, & Wilson,
1999; Mach et aI., 1999; Hermann, Van Kooten, Gaillard, Banchereau, & Blanchard,
1995). Therefore, CD40L is recognized as a rate-limiting step in proper immune system
function and overall human health.
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Experiments were performed to assess the impact of DEP on activated cells, as
individuals living with existing health conditions including asthma and other respiratory
diseases, are considered to be at higher risk to the deleterious effects of DEP (Holguin,
2008). By delaying the introduction ofDEP 6 h following TCR activation, the effect of
DEP on previously activated cells was evaluated. Following DEP treatment, CD40L
expression was significantly greater than in cells with TCR activation alone (Fig. 3). In
comparison, DEP treatment elicited no effect on TCR-induced CD69 or CD25 expression
further supporting CD40L as a novel target for negative effects of DEP exposure (Fig. 3).
These findings have relevance to asthma and certain autoimmune disorders, as these
diseases are characterized by the presence ofunderIying low level T cell activation
(Schonbeck, Mach, & Libby, 2000). To further evaluate the effect ofDEP on CD40L,
cells were concurrently provided DEP in the context of optimal T cell activation
involving TCR and CD28 costimulation, mimicking DEP exposure in the context of
antigen-induced T cell activation. Consistent with previous findings, only CD40L
expression was augmented in cells provided optimal activation (Fig. 4). Again, these
results indicate that DEP may uniquely affect CD40L expression, and may provide
further support for DEP as an adjuvant in immune system activation as described by
others (Samuelsen, Nygaard, & Lovik, 2008; van Zijverden et aI., 2000; Finkelman et aI.,
2004). Given that CD40L is an essential immune component and individuals with
chronic low-level expression of this protein are considered to be an at-risk population, the
ability of DEP to alter signaling pathways responsible for immune system activation
needs to be further addressed as this may provide a pivotal piece of information as to how
DEP elicits its effects on human health.
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CD40L-mediated immune responses are not solely based upon the action of the
membrane-bound protein but also via a soluble secreted factor. Soluble CD40L
(sCD40L) exists as a truncated 18 kDa protein produced by the proteolytic cleavage of
the full length 28-33 kDa membrane-bound form (Graf et aI., 1995). Despite this
truncation, sCD40L possesses appreciable biological activity, although to a lesser extent
than membrane CD40L, and elevated sCD40L has been associated with a variety of
human diseases including atherosclerosis, inflammatory bowel disease, and SLE
(Aukrust et aI., 1999; Kato et aI., 1999; Ludewig, Henn, Schroder, Graf, & Kroczek,
1996). Based on the observation that expression of membrane and soluble CD40L appear
to be differentially regulated (Matthies, Newman, Hodzic, & Wingett, 2006), experiments
were conducted to evaluate the effects ofDEP on both protein isoforms. Our
experiments showed that in contrast to the increased expression of membrane CD40L
(Figs. 1-2), DEP was insufficient to induce sCD40L in the absence of stimuli (Figs. 8-9).
Studies combining DEP treatment with optimal T cell signaling further magnified this
differential production of membrane CD40L. Specifically, evaluation of both isoforms
showed a significant change in the expression of both protein forms, albeit in an inverse
relationship, with an increase in membrane CD40L (Fig. 4) and a decrease in the
production of sCD40L (Fig. 9). The preferential expression of membrane CD40L is
significant as this isoform possesses superior biological activity in comparison to the
soluble form and would be expected to elicit a stronger immune response (Ludewig,
Henn, Schroder, Graf, & Kroczek, 1996). To further investigate this effect, experiments
were performed to isolate the different signaling components of T cell activation to
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determine if a specific pathway was affected by DEP, or if the effect was a global
response.
Dissection of the TCR generated signals into the PKC and calcium pathways
highlighted the larger contribution ofDEP to induce PKC-dependent membrane CD40L
induction. While PKC-induced membrane CD40L (Figs. 5 and 8) was markedly
increased following DEP exposure, sCD40L levels were decreased (Fig. 8). Calcium
signaling also clearly increased membrane CD40L expression (Fig. 6 and 8), although not
to the extent ofPKC, and had no appreciable effect on DEP regulated sCD40L
expression (Fig. 8). Further studies to evaluate sCD40L regulation by DEP were
employed to mimic physiological activation ofT cells by TCR and CD28 co stimulation.
Membrane CD40L (Fig. 7) was augmented by DEP while sCD40L was again downregulated (Fig. 9A) further suggesting a preferential production of membrane CD40L.
Interestingly, the only activation scenario that resulted in an induction of both
membrane and soluble CD40L following DEP exposure was in experiments utilizing
dbcAMP to mimic

~-adrenergic

agonists, medications commonly utilized in asthma

treatment. In the context of asthma, aberrant CD40L expression may be one of many
factors contributing to disease pathogenesis as supported by animal model studies
(Mehlhop et aI., 2000). Along these lines, research indicates that

~-agonists

can alter the

expression of CD40L. Specifically, in a population of asthmatic patients following
treatment with

~-adrenergic

agonist medications, and other agents that increase cAMP,

an increase in CD40L expression was observed (Wingett, Forcier, & Nielson, 1999).
Acting as a second messenger, cAMP mediates the signals that regulate a host of T cell
functions such as proliferation and cytokine production via both inhibitory and
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stimulatory activities (Lacour et aI., 1994; Desai-Mehta, Lu, Ramsey-Goldman, & Datta,
1996). As cAMP further amplifies Ca2+-induced CD40L expression (Wingett, Forcier, &
Nielson, 1999), we evaluated the effect ofDEP exposure on cells costimulated with
ionomycin and dbcAMP. The stimulatory property of cAMP to increase CD40L was
enhanced in T cells exposed to DEP as measured by a modest, yet significant increase in
the production of both membrane and soluble CD40L (Fig. 13). While the previously
shown increase in membrane CD40L is a considerable finding, the increase in both
isoforms of CD40L in cells treated with

cAMP/~-agonists

is noteworthy as individuals

with chronic respiratory disease are far more susceptible to the injurious health effects of
DEP. The ability ofDEP to increase CD40L, when combined with cAMP-inducing
agents, may in some way contribute to the increased severity of asthma symptoms
occurring in recent years, and illustrates the importance of appropriate warning systems
to alert at-risk individuals when environmental PM levels exceed acceptable ranges.
As the production of sCD40L is thought to involve the process of proteolytic
cleavage, experiments were conducted to evaluate the effects ofDEP on this mechanism,
also known as shedding. While not completely elucidated, shedding is understood to be
an important mechanism for regulating immune cell signaling by either reducing the
amount of receptor proteins on the cell surface or by releasing soluble domains of
proteins, which retain similar biological ability to their membrane-bound counterparts
(Schlondorff & Blobel, 1999). The proteolytic cleavage mechanism implicated in the
production of sCD40L, and other TNF family members, involves the action of the
ADAM (a disintegrin and metalloproteinase) family proteins, including the ADAM-I0
protease (Matthies, Newman, Hodzic, & Wingett, 2006). ADAM-I0 mediated
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proteolytic cleavage results in the production of a truncated, yet biologically active,
CD40L protein with a molecular weight at -18 kDa, in contrast to full length 28-33 kDa
membrane-bound CD40L (Mazzei et aI., 1995). As the production of sCD40L was
down-regulated following DEP exposure in almost every activation scenario utilized in
our studies, it was hypothesized that DEP was inhibiting the process of shedding by
acting upon ADAM-l O. Therefore, a recombinant chimeric fusion protein system was
employed to assess whether ADAM-1O function was affected by DEP. Specifically, a
murine recombinant protein was utilized that contained the putative cleavage site
(methionine at position 113 in the extracellular region) that results in the production of
the 18 kDa native sCD40L. A schematic representation of the murine CD40L-CD33
fusion protein, which contains the extracellular domain ofCD40L, is shown in Fig. 14.
Consistent with previous reports (Matthies, Newman, Hodzic, & Wingett, 2006) and as
shown in Fig. 10, a distinct 32 kDa band corresponding to the membrane CD40L protein
was visualized with the cleaved 18 kDa band corresponding to sCD40L present only in
ADAM-l 0 treated samples. Of interest, the appearance of a second, distinct cleavage
product was observed in ADAM-1O samples (-9 kDa) and may represent a secondary
cleavage event. As expected, the appearance of the -9 and 18 kDa cleavage products was
also correlated with the decreasing intensity of the full length protein. In order to identify
a potential amino acid sequence for the secondary cleavage event, the Biology
WorkBench Pattern Match program was utilized. This program is provided by the
University of California, San Diego Supercomputer Center. The fusion protein construct
was analyzed for the presence of the putative ADAM-l 0 cleavage sequence responsible
for the production of soluble tumor necrosis factor (TNF -a) (Rosendahl et aI., 1997) since
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CD40L and TNF-a are structurally related and belong to the same super family of
proteins (Bossen et aI., 2006). While the exact sequence for TNF-a was not found, it is
important to note that a detailed series of studies have been performed where amino acid
substitutions in the putative TNF -a cleavage site were made and found to have varying
effects on ADAM-tO proteolytic activity. Therefore, our analyses were extended to
include these amino acid substitutions, especially given the increasingly recognized lack
of ADAM-l 0 consensus cleavage sequences among characterized substrates to date
(Rosendahl et aI., 1997). Using this approach, a putative core cleavage sequence starting
at amino acid 184 (SSQR) of the CD40L protein was identified, which may represent a
second cleavage site. As described for various TNF-a amino acid substituted peptides,
only the substitution of amino acid 77 from an alanine to serine was found to reduce the
ability of ADAM-l 0 to cleave TNF-a

(~39%),

while the other three amino acids

conferred 100% ADAM-l 0 mediated cleavage relative to the wild-type substrate
(Rosendahl et aI., 1997).
The known cleavage sites for ADAM-l 0 substrates are listed in Table 1,
emphasizing the variability between amino acid sequences which makes the
determination of a well-defined putative cleavage site difficult given the current state of
knowledge regarding ADAM-l O. Given that the amino acid sequences at substrate
cleavage sites are highly variable, it is thought that structural and kinetic characteristics
are more important than minimal amino acid sequence (Amour et aI., 2000). In this
regard, it is important to note that a region of significant homology

(~86%)

surrounds the

putative second cleavage site between CD40L and TNF-a as determined using the Basic
Local Alignment Search Tool (BLAST). This protein sequence analysis found an
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alignment (12 out of 14 amino acids) between the two proteins from amino acids 165 180 in the CD40L extracellular domain. This TNF-like structural domain could
potentially playa larger role in directing ADAM-l 0 to the second cleavage site in the
CD40L protein than the individual amino acids themselves. The observation that DEP
increased the abundance of the 18 kDa band, while markedly decreasing the intensity of 9
kDa band suggests that DEP can alter the activity of ADAM-l 0 to proteolytically process
CD40L.
To fully understand the role ofDEP on ADAM-l 0 function, further experiments
are needed to investigate the cleavage events occurring within the CD40L fusion
construct. Specifically, various antibodies directed against different regions of the
CD40L extracellular domain could be utilized in Western blot experiments to
conclusively demonstrate the occurrence of a secondary cleavage event, as the current
polyclonal antibody detects both the -18 kDa and 9 kDa protein cleavage products.
Additional supporting experiments to evaluate the effects of ADAM-l 0 mediated
cleavage on other known cleavage sites such as TNF-a or p-amyloid precursor protein
(Table 1) are needed and would further elucidate the role ofDEP on this matrix
metalloproteinase.
An alternative explanation of the ADAM-lO Western blot results may be
considered based on observations that the intensity of the -32 kDa band corresponding to
membrane CD40L appeared to decrease in samples containing DEP, without the
appearance of the cleaved sCD40L product. In this cell-free system, the carbon core
could bind to the CD40L fusion protein, resulting in the formation of high molecular
weight aggregates. The presence of its carbonaceous core, an instrumental component of
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DEP, can bind indiscriminately to various proteins and could lead to the formation of
these aggregates, which would subsequently interfere with protein migration as the large
molecular weight aggregates would fail to enter the acrylamide matrix. While it is
possible that the 9 kDa product could be preferentially adsorbed to the carbon core
relative to the 18 kDa product, the basis for this preferential adherence remains presently
unclear. Nevertheless, ADAM-to function may be altered by DEP and additional studies
are needed to further address the impact of DEP exposure on ADAM-l 0 function.
While the results of our cell-free recombinant protein assay indicate that DEP
may alter the function of ADAM-IO with respect to proteolytic cleavage ofCD40L, these
results are not readily resolvable with our cell-based sCD40L studies, which demonstrate
a DEP-induced inhibition of sCD40L. We believe that the results of our cell-based assay
represents a more physiological, and consequently more meaningful result as this system
allows for evaluation of sCD40L as a combination of multiple mechanisms. Our cell-free
system suggests that the down-regulation of sCD40L is not mediated by extracellular
ADAM-l 0 but does not allow for the evaluation of other potential mechanisms
responsible for the production of sCD40L. Recent observations do suggest that ADAM10 proteolysis can also occur within intracellular compartments. A close link was
reported between the transport ofTNF-a to the cell surface and its cleavage (Arribas et
aI., 1996) and ADAM-l 0 appears responsible for the shedding of at least two proteins,
CD44 and Ll, in vesicles (Stoeck et aI., 2006). Alternatively, sCD40L may be generated
via an intracellular proteolytic event directly following protein synthesis since low levels
have been detected in microsomes (Pietravalle et aI., 1996). Alternate mechanisms for
the production of sCD40L have been suggested such as alternative splicing to eliminate
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transmembrane regions or the usage of alternate transcription initiation start sites,
although no direct evidence has implicated these mechanisms in the production of
sCD40L (Graf et aI., 1995). Additionally, no Kozak consensus sequence in the
corresponding nucleotide sequence is present allowing for alternative translation
initiation. Another form of the soluble CD40L protein has been reported and begins at a
slightly different amino acid position (Gln-114 instead of Met-113) and transfectants
lacking nucleotides corresponding to the first 12 amino acids of full-length CD40L fail to
express either membrane or soluble protein (Hsu et aI., 1997). It is probably most likely
that sCD40L production relies on a combination of intracellular processing and
membrane cleavage events and further studies are needed to resolve the effect ofDEP on
these processes as the recombinant cell free system utilized in the ADAM-l 0 studies is
unable to .evaluate the contributions of different cleavage mechanisms to the in vitro
production of sCD40L.
As DEP was found to alter the expression of membrane and soluble TH cell
activation markers, evaluation of other soluble immune mediators was conducted. These
factors in general, known as cytokines, exert immune system control at distant sites in the
body via the circulatory system. Specifically, the expression of IL-8 and IL-17 were
evaluated following DEP exposure. Both IL-8 and IL-17 are considered to be proinflammatory cytokines as these factors have been linked with allergic and autoimmune
diseases such as asthma, atherosclerosis, MS, and Crohn's disease (Grimm, Elsbury,
Pavli, & Doe, 1996; Apostolakis, Vogiatzi, Arnanatidou, & Spandidos, 2009; Miossec,
2009; Hashimoto, Akiyama, Kobayashi, & Mori, 2005). Samples from individuals with
asthma showed an increase in IL-8 and IL-17 expression with animal models
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demonstrating the importance of these two cytokines in asthma pathogenesis (Hashimoto,
Akiyama, Kobayashi, & Mori, 2005; Pease & Sabroe, 2002; Wang & Liu, 2008). TH
cells are known to produce both IL-8 and IL-17 with IL-17 being a T H cell specific
cytokine. While no appreciable effect on IL-8 was observed following DEP exposure, a
3-fold decrease in IL-17 production occurred (Fig. 11). While it is accepted that
environmental toxins such as DEP can suppress immune system function (Siegel et aI.,
2004), IL-8 expression was not affected suggesting that the immunosuppressant capacity
of DEP is not widespread to all cytokines. The biological relevance of decreased IL-17
may have multiple, and even complex consequences, as the effect of this cytokine varies
according to disease state and the context of other cytokines present. For example, IL-17
appears to be important for initiating asthma pathogenesis, but later can act as a negative
regulator of asthma as blocking of IL-17 function in a mouse model exacerbates disease
state (Schnyder-Candrian et aI., 2006; Wang & Liu, 2008). Therefore, further
investigation into the effects of DEP on IL-17 production, in the context of healthy and
at-risk populations, needs to be addressed to evaluate whether or not a decrease in this
cytokine in IL-17 contributes to or alleviates the impacts of D EP.
Based on the observed immunoregulatory properties, the effect of DEP on
T cell cytotoxicity was evaluated. As shown in Fig. 12, no evidence of cytoxicity was
observed as measured by propidium iodide (PI) staining, which measures changes in cell
membrane permeability and is a classical indicator of cell death (Riccardi & Nicoletti,
2006). The failure ofDEP to affect cytotoxicity in resting cells is interesting given that
in vitro studies demonstrate death in other cell types, including bronchial epithelial cells,

lung cells, and alveolar macrophages as a result ofDEP (Nel, Diaz-Sanchez, & Li, 2001;
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Wan & Diaz-Sanchez, 2007). Further studies are needed to assess the affect ofDEP on
viability in activated cells as they exhibit greater metabolic activity and may respond
differently than resting cells.
In conclusion, the results presented here provide evidence for an
immunomodulatory effect ofDEP on TH cell with changes in the expression of key
activation markers and cytokines. Of the activation markers evaluated, the expression of
CD40L appeared to be differentially affected by DEP exposure with an increase in the
expression of membrane CD40L in the context of every in vitro activation model utilized,
without parallel increases in the other membrane-bound activation markers. Concurrent
evaluation of the effects ofDEP on both naturally occurring forms ofCD40L highlighted
the preferential induction of membrane CD40L expression, with a parallel decrease in the
soluble version of this protein, with cAMP induction being the only exception.
Therefore, the increased expression of the membrane-bound CD40L isoforms, which
possesses greater inherent biological activity, is significant as the deleterious effects
would be proportionally larger in individuals with allergic disorders including asthma.
An alteration in the processes responsible for the production of sCD40L was also

reported. In the context of cAMP signaling, the increased expression of both membrane
and soluble CD40L following DEP would be expected to have more biological
significance for the individual as both isoforms can induce the same down-stream
signaling events. Also, as many medications act through the important cAMP second
messenger, the impact of DEP would be very relevant to individuals with existing health
conditions, who are predisposed to the harmful health effects of this common pollutant.
D EP exposure also suppressed the production of IL-17, an important cytokine with
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pleiotropic effects involved in the pathogenesis of asthma and other allergic diseases.
Importantly, all of these immunomodulatory effects occurred in the absence of
cytotoxicity. As diesel fuel continues to be a vital component of daily activity for all
individuals living in industrialized nations, further research is needed to understand the
molecular mechanisms occurring after DEP inhalation. Based on the research presented,
which further supports an already existing body of knowledge, it is clear that steps need
to be taken to minimize these effects and improve overall air quality. Future directions
need to focus on understanding the mechanisms by which DEP affect immune cells, in
addition to other cell types, to fully understand the implications of exposure. As
standards and filtration systems improve, research will need to evaluate whether or not
these improvements result in an increased quality of life. In addition, as alternative fuel
usage increases, studies will need to be conducted to verify that the combustion byproducts of these fuels lack the same risks as current fuels. The end result of this
research will hopefully result in the creation and implementation of more stringent air
quality standards to protect individuals exposed to common air particulate matter
pollutants such as diesel exhaust particles.
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Protein

Se9uence

Reference
(Ludewig, Henn, Schroder,
Graf, & Kroczek, 1996)
(Rosendahl et aI., 1997; Black et
aI., 1997)
(Mullberg et aI., 1995)

CD40L

SFEM*QRGD

Pro-TNF

LAQA*VRSS

IL-6 Rece.etor
TNFR-55
TNFR-75
Pro-TFG-a

LPVQ*DSSS
QIEN*VKGT
APGA*VHLP
DLLA*VVAA

c-kit ligand-l

PVAA*SSLR

(Pandiella, Bosenberg, Huang,
Besmer, & Massague, 1992)

~-Arnyloid

HHQK*LVFF
DSGY*EVHH

(Allinson et aI., 2004; Asai et
al.,2003)

Angiotensin-converting enzyme

AGQR*LATA

(Oppong, Turner, & Hooper,
1993)

L -selectin

Myelin Basic Protein-l

KLDK*SFSM
GSLP*QKSQ

Delta-Like 1

SERH*MESQ

(Six et aI., 2003; Dyczynska et
al.,2007)

PSKE*RNGK

(Hinkle et aI., 2004)

precursor protein

Heparin-binding EGF-like growth
factor
Transforming growth factor a
Prion protein preproprotein
Fc fragment of IgE,
CD23A low affinity II
E.eh rece12tor B2

VAAA*VVSH
NMKH*MAGA
RAEQ*QRLK
DQMA*QKSQ
EYQT*SIKE

(Mullberg et aI., 1995)
(Crowe et aI., 1995)
(Black et aI., 1997)

(Rosendahl et aI., 1997)
(Naus et aI., 2006)

(Hinkle et aI., 2003)
(Laffont-Proust et aI., 2005)
(Lemieux et aI., 2007)
(Litterst et aI., 2007)

Table 1. ADAM-lO proposed proteolytic cleavage sites. The experimentally determined

cleavage sites for known ADAM-I 0 substrates. Cleavage sites are indicated by an * in
the given amino acid sequence.
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Figure 1. Diesel exhaust particles increase CD40L expression on unactivated T helper
cells. Purified CD4+ T cells were incubated for 24 h in the presence ofDEP, stained with
anti-CD40L, CD69, and CD25 Abs, and subsequently analyzed via flow cytometry.
Results depict the percentage of positively staining cells and error bars depict standard
error (SE). A) CD40L expression, n= 6. B) CD69 expression, n=6. C) CD25 expression,
n=6. Statistical significance was determined using a paired T test,
p < 0.0001.
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Figure 2. Concentration dependent increase in membrane CD40L by DEP. Freshly
purified CD4+ T cells were treated with different concentrations of DEP and CD40L
expression was analyzed via flow cytometry. Results depict the percentage of CD40L
positive cells and error bars depict SE, n=6. Statistical significance was determined using
a repeated measures ANOVA,

* = P < 0.05, and *** = p < 0.0001.
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Figure 3. Effects ofDEP on CD3 activated T cells. CD4+ T cells were cultured with

anti-CD3 mAb for 6 h and transferred to fresh culture wells. Cells were then treated with
DEP (800 /lg/ml) for an additional 18 h and CD40L expression evaluated using flow
cytometry. Data is presented as percentage of CD40L positive cells, and error bars depict
SE. A) CD40L expression, n=4 B) CD69 expression, n=3 C) CD25 expression, n=3 .
Significance was determined using a paired T test,

*=p

< 0.05.
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Figure 4. Effects of DEP on CD28 costimulated T cells. CD4+ T cells were stimulated

with Dynabeads® ± DEP (800 /-lg/ml) for 24 h. Surface expression of each respective T
cell activation marker was analyzed using flow cytometry, n=3 , with error bars depicting
SE. Panel A) CD40L expression, B) CD69 expression, and C) CD25 expression.
Significance was determined using a repeated measures ANOVA,

* = p < 0.05.
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Figure 5. DEP augments PKC-dependent CD40L protein expression. CD4+ T cells were

stimulated with PMA ± DEP (800 Jlg/ml) for 24 h and expression of activation markers
evaluated by flow cytometry. A) CD40L expression in PMA (2 ng/ml) ± DEP treated
cells, n=7. B) CD25 expression in PMA (0.5 ng/ml) ± DEP treated cells, n=3. C) CD69
expression in PMA (0.5 ng/ml) ± DEP treated cells, n=3. Error bars depict SE with
asterisks indicating statistical significance,

* = p < 0.05 and *** = p < 0.0001.
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Figure 6. DEP augments calcium-dependent CD40L expression. CD4+ T cells were
stimulated with ionomycin 0.75 11M ± DEP (800 Ilg/ml) for 24 h and changes in protein
expression evaluated using flow cytometry. Panel A) CD40L expression, panel B) CD69
expression triplicate, and panel C) CD25 expression. CD40L data, n=5, and CD25 and
CD69 data presented are from a representative experiment performed in triplicate. Error
bars depict SE with asterisks indicating statistical significance,
0.001.
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Figure 7. DEP induces CD40L in PMA and ionomycin activated cells. CD4+ T cells

were stimulated with varying amounts of ionomycin and PMA ± DEP (800 Jlg/ml) for 24
h and changes in CD40L expression evaluated using flow cytometry. The percentage of
CD40L positive staining cells from a representative experiment performed in triplicate is
shown. Error bars depict SE with asterisks indicating statistical significance,
0.05 and

*** = p

< 0.0001.
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Figure 8. Membrane and soluble CD40L expression are differentially regulated by DEP.
CD4+ T cells were stimulated with ionomycin (0.75 JlM) or PMA (2.0 nglml) for 24 h.
Cells were dual harvested and concurrently analyzed for soluble and membrane CD40L
expression by ELISA and flow cytometry, respectively. Panel A) PMA-induced
membrane CD40L B) PMA-induced soluble CD40L C) Ionomycin-induced membrane
CD40L D) Ionomycin-induced soluble CD40L. Data above represents n=4 and error bars
depict SE. Significance was determined using a repeated measures ANOVA,
and

*** = p< 0.0001.

* = p< 0.05
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Figure 9. T cell receptor induced soluble CD40L expression is inhibited by DEP. CD4+
T cells were stimulated through the TCR via ionomycin (0.75 11M) + PMA (2.0 ng/ml) or

CD3/CD28 Dynabeads® for 24 h. Cells were dual harvested and concurrently analyzed
for soluble and membrane CD40L expression by ELISA and flow cytometry,
respectively. Panel A) IonlPMA induced sCD40L n=3 B) CD3/CD28 induced sCD40L
n=4. Error bars depict SE and significance was determined by paired T test,

* = p< 0.05 .
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Figure 10. Effects ofDEP on ADAM-1 0 mediated proteolytic cleavage ofCD40L.

Murine CD40LlCD33 fusion protein (0.5 f!g) was incubated with 20 f!g/ml recombinant
human ADAM-1 0, with (lane 4) or without 800 f!g DEP (lane 3), for 5 hat 37°C in 25 f!l
of total reaction mixture. The mixture was then fractionated by 10% SDS polyacrylamide gel electrophoresis under reducing conditions. Processed and full-length
CD40L fusion proteins were detected by Western blotting using a goat-polyclonal
antibody for the extracellular domain ofCD40L. Lane 1, CD40L fusion protein; lane 2,
CD40L fusion protein and DEP; lane 3, CD40L fusion protein and rADAM-I 0; lane 4,
CD40L fusion protein, rADAM-lO, and DEP.
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Figure 11. Production ofIL-17 is down regulated following DEP exposure. CD4+ T

cells were stimulated with CD3/CD28 Dynabeads® ± DEP (800 Ilg/ml) for 24 h and cell
free supernatants were analyzed for IL-8 and IL-17 cytokine production. Panel A) IL-17
n=6 B) IL-8 n=5. Error bars depict SE and significance was determined using a paired T
test, * = p <0.05.
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Figure 12. DEP fails to appreciably affect T cell viability. Purified CD4+ T cells

(>95%) were treated with increasing concentrations ofDEP for 24 h and cell viability
evaluated using propidium iodide staining and flow cytometry. Results are depicted in
percent viability from three independent experiments and error bars depict SE.
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induced membrane and soluble CD40L expression is heightened

after DEP exposure. CD4+ T cells were stimulated with ionomycin (0.75 flM) ± db cAMP
(l OOflm) ± DEP for 24 h. Cells were harvested and analyzed concurrently for membrane

and soluble CD40L expression by ELISA. Panel A) Membrane CD40L, n=4; B) Soluble
CD40L one representative experiment performed in triplicate. Error bars depict SE.
p < 0.05 and

*** = p

< 0.0001.
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Figure 14. A schematic representation of the ADAM-I0 cleavage sites located in the
murine CD33-CD40L fusion protein. The proposed cleavage site at position 112-116, (*,
EMQR) results in the production of an -18 kDa band, representing sCD40L. A second
cleavage site was identified using the Biology WorkBench Pattern Recognition Program
created by the University of California, San Diego Supercomputer Center. The site at
position 184-188 (**, SSQR), related to the known TNF-a cleavage sequence, may result
in the production of the secondary cleavage product of 9 kDa.

